FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2178775247> ?p ?o ?g. }

• W2178775247 endingPage "2019" @default.
• W2178775247 startingPage "2009" @default.
• W2178775247 abstract "Abstract Purpose: Activating PIK3CA genomic alterations are frequent in head and neck squamous cell carcinoma (HNSCC), and there is an association between phosphoinositide 3-kinase (PI3K) signaling and radioresistance. Hence, we investigated the therapeutic efficacy of inhibiting PI3K with GDC-0032, a PI3K inhibitor with potent activity against p110α, in combination with radiation in HNSCC. Experimental Design: The efficacy of GDC-0032 was assessed in vitro in 26 HNSCC cell lines with crystal violet proliferation assays, and changes in PI3K signaling were measured by Western blot analysis. Cytotoxicity and radiosensitization were assessed with Annexin V staining via flow cytometry and clonogenic survival assays, respectively. DNA damage repair was assessed with immunofluorescence for γH2AX foci, and cell cycle analysis was performed with flow cytometry. In vivo efficacy of GDC-0032 and radiation was assessed in xenografts implanted into nude mice. Results: GDC-0032 inhibited potently PI3K signaling and displayed greater antiproliferative activity in HNSCC cell lines with PIK3CA mutations or amplification, whereas cell lines with PTEN alterations were relatively resistant to its effects. Pretreatment with GDC-0032 radiosensitized PIK3CA-mutant HNSCC cells, enhanced radiation-induced apoptosis, impaired DNA damage repair, and prolonged G2–M arrest following irradiation. Furthermore, combined GDC-0032 and radiation was more effective than either treatment alone in vivo in subcutaneous xenograft models. Conclusions: GDC-0032 has increased potency in HNSCC cell lines harboring PIK3CA-activating aberrations. Further, combined GDC-0032 and radiotherapy was more efficacious than either treatment alone in PIK3CA-altered HNSCC in vitro and in vivo. This strategy warrants further clinical investigation. Clin Cancer Res; 22(8); 2009–19. ©2015 AACR." @default.
• W2178775247 created "2016-06-24" @default.
• W2178775247 creator A5002819777 @default.
• W2178775247 creator A5004300577 @default.
• W2178775247 creator A5016127308 @default.
• W2178775247 creator A5026014632 @default.
• W2178775247 creator A5034938154 @default.
• W2178775247 creator A5037931371 @default.
• W2178775247 creator A5052610122 @default.
• W2178775247 creator A5056895130 @default.
• W2178775247 creator A5066423056 @default.
• W2178775247 creator A5067395984 @default.
• W2178775247 creator A5075136197 @default.
• W2178775247 creator A5082662801 @default.
• W2178775247 creator A5084443648 @default.
• W2178775247 date "2016-04-14" @default.
• W2178775247 modified "2023-10-13" @default.
• W2178775247 title "Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating <i>PIK3CA</i> Alterations" @default.
• W2178775247 cites W1600510649 @default.
• W2178775247 cites W1984621921 @default.
• W2178775247 cites W1985585626 @default.
• W2178775247 cites W1986241711 @default.
• W2178775247 cites W2004637409 @default.
• W2178775247 cites W2036005555 @default.
• W2178775247 cites W2043398720 @default.
• W2178775247 cites W2057366353 @default.
• W2178775247 cites W2059426385 @default.
• W2178775247 cites W2062312459 @default.
• W2178775247 cites W2065434335 @default.
• W2178775247 cites W2067342462 @default.
• W2178775247 cites W2067427915 @default.
• W2178775247 cites W2071463092 @default.
• W2178775247 cites W2086997734 @default.
• W2178775247 cites W2087693130 @default.
• W2178775247 cites W2089257078 @default.
• W2178775247 cites W2092000556 @default.
• W2178775247 cites W2101400486 @default.
• W2178775247 cites W2101816193 @default.
• W2178775247 cites W2101982508 @default.
• W2178775247 cites W2109252212 @default.
• W2178775247 cites W2111442242 @default.
• W2178775247 cites W2114119309 @default.
• W2178775247 cites W2117988802 @default.
• W2178775247 cites W2119886330 @default.
• W2178775247 cites W2119999819 @default.
• W2178775247 cites W2120806256 @default.
• W2178775247 cites W2122357705 @default.
• W2178775247 cites W2125919881 @default.
• W2178775247 cites W2130084494 @default.
• W2178775247 cites W2131660936 @default.
• W2178775247 cites W2137124072 @default.
• W2178775247 cites W2140753782 @default.
• W2178775247 cites W2143254803 @default.
• W2178775247 cites W2146488048 @default.
• W2178775247 cites W2149441684 @default.
• W2178775247 cites W2153096480 @default.
• W2178775247 cites W2154152644 @default.
• W2178775247 cites W2155384808 @default.
• W2178775247 cites W2156918228 @default.
• W2178775247 cites W2159581459 @default.
• W2178775247 cites W2168500439 @default.
• W2178775247 cites W2509319388 @default.
• W2178775247 doi "https://doi.org/10.1158/1078-0432.ccr-15-2245" @default.
• W2178775247 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4870591" @default.
• W2178775247 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26589432" @default.
• W2178775247 hasPublicationYear "2016" @default.
• W2178775247 type Work @default.
• W2178775247 sameAs 2178775247 @default.
• W2178775247 citedByCount "69" @default.
• W2178775247 countsByYear W21787752472016 @default.
• W2178775247 countsByYear W21787752472017 @default.
• W2178775247 countsByYear W21787752472018 @default.
• W2178775247 countsByYear W21787752472019 @default.
• W2178775247 countsByYear W21787752472020 @default.
• W2178775247 countsByYear W21787752472021 @default.
• W2178775247 countsByYear W21787752472022 @default.
• W2178775247 countsByYear W21787752472023 @default.
• W2178775247 crossrefType "journal-article" @default.
• W2178775247 hasAuthorship W2178775247A5002819777 @default.
• W2178775247 hasAuthorship W2178775247A5004300577 @default.
• W2178775247 hasAuthorship W2178775247A5016127308 @default.
• W2178775247 hasAuthorship W2178775247A5026014632 @default.
• W2178775247 hasAuthorship W2178775247A5034938154 @default.
• W2178775247 hasAuthorship W2178775247A5037931371 @default.
• W2178775247 hasAuthorship W2178775247A5052610122 @default.
• W2178775247 hasAuthorship W2178775247A5056895130 @default.
• W2178775247 hasAuthorship W2178775247A5066423056 @default.
• W2178775247 hasAuthorship W2178775247A5067395984 @default.
• W2178775247 hasAuthorship W2178775247A5075136197 @default.
• W2178775247 hasAuthorship W2178775247A5082662801 @default.
• W2178775247 hasAuthorship W2178775247A5084443648 @default.
• W2178775247 hasBestOaLocation W21787752471 @default.
• W2178775247 hasConcept C117262875 @default.
• W2178775247 hasConcept C126322002 @default.
• W2178775247 hasConcept C143425029 @default.
• W2178775247 hasConcept C150903083 @default.
• W2178775247 hasConcept C153911025 @default.
• W2178775247 hasConcept C190283241 @default.

• next